Pen­ny stock biotech His­to­gen stops de­vel­op­ment pro­grams and con­sid­ers strate­gic al­ter­na­tives

The pen­ny stock biotech His­to­gen has halt­ed its de­vel­op­ment pro­grams and is ex­plor­ing strate­gic al­ter­na­tives for the fu­ture of the im­mune sys­tem-fo­cused com­pa­ny, a few …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER